Schroder Investment Management Group’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-649,980
| Closed | -$62.1M | – | 1219 |
|
|
2024
Q1 | $62.1M | Buy |
+649,980
| New | +$54.6M | 0.07% | 243 |
|
|
2023
Q1 | – | Sell |
-519,916
| Closed | -$38.8M | – | 1274 |
|
|
2022
Q4 | $38.8M | Sell |
519,916
-272,134
| -34% | -$21M | 0.06% | 312 |
|
|
2022
Q3 | $65.4M | Sell |
792,050
-1,949,897
| -71% | -$188M | 0.11% | 186 |
|
|
2022
Q2 | $261M | Sell |
2,741,947
-148,319
| -5% | -$15.4M | 0.4% | 53 |
|
|
2022
Q1 | $338M | Buy |
2,890,266
+5,393
| +0.2% | +$605K | 0.45% | 48 |
|
|
2021
Q4 | $374M | Buy |
2,884,873
+629,868
| +28% | +$73.5M | 0.49% | 42 |
|
|
2021
Q3 | $255M | Sell |
2,255,005
-46,399
| -2% | -$5.3M | 0.39% | 51 |
|
|
2021
Q2 | $238M | Buy |
2,301,404
+317,053
| +16% | +$29.9M | 0.3% | 68 |
|
|
2021
Q1 | $166M | Sell |
1,984,351
-261,566
| -12% | -$22.1M | 0.22% | 94 |
|
|
2020
Q4 | $205M | Sell |
2,245,917
-203,116
| -8% | -$16.8M | 0.29% | 74 |
|
|
2020
Q3 | $193M | Buy |
2,449,033
+1,443,976
| +144% | +$113M | 0.31% | 66 |
|
|
2020
Q2 | $69.5M | Buy |
1,005,057
+630,450
| +168% | +$44.8M | 0.13% | 160 |
|
|
2020
Q1 | $24.4M | Sell |
374,607
-68,238
| -15% | -$4.92M | 0.05% | 331 |
|
|
2019
Q4 | $34.4M | Buy |
442,845
+336,210
| +315% | +$26.3M | 0.06% | 362 |
|
|
2019
Q3 | $7.72M | Sell |
106,635
-7,848
| -7% | -$551K | 0.01% | 673 |
|
|
2019
Q2 | $7.05M | Buy |
114,483
+60,489
| +112% | +$3.66M | 0.01% | 639 |
|
|
2019
Q1 | $3.44M | Sell |
53,994
-1,806
| -3% | -$103K | 0.01% | 746 |
|
|
2018
Q4 | $2.85K | Sell |
55,800
-39,534
| -41% | -$2M | 0.01% | 756 |
|
|
2018
Q3 | $5.53M | Sell |
95,334
-34,830
| -27% | -$1.7M | 0.01% | 685 |
|
|
2018
Q2 | $6.37M | Sell |
130,164
-43,713
| -25% | -$2.04M | 0.01% | 677 |
|
|
2018
Q1 | $8.09M | Sell |
173,877
-303,135
| -64% | -$13.2M | 0.01% | 650 |
|
|
2017
Q4 | $17.9M | Buy |
477,012
+100,800
| +27% | +$3.7M | 0.03% | 528 |
|
|
2017
Q3 | $13.7M | Sell |
376,212
-79,863
| -18% | -$3.05M | 0.02% | 554 |
|
|
2017
Q2 | $17.8M | Sell |
456,075
-260,043
| -36% | -$9.49M | 0.03% | 501 |
|
|
2017
Q1 | $22.4M | Buy |
716,118
+548,412
| +327% | +$17.2M | 0.04% | 456 |
|
|
2016
Q4 | $5.24M | Buy |
167,706
+110,106
| +191% | +$3.57M | 0.01% | 709 |
|
|
2016
Q3 | $2.31M | Buy |
57,600
+56,100
| +3,740% | +$2.11M | ﹤0.01% | 821 |
|
|
2016
Q2 | $50K | Buy |
+1,500
| New | +$51.3K | ﹤0.01% | 1093 |
|
|
2015
Q4 | – | Sell |
-18,240
| Closed | -$432K | – | 1196 |
|
|
2015
Q3 | $432K | Sell |
18,240
-395,298
| -96% | -$9.54M | ﹤0.01% | 974 |
|
|
2015
Q2 | $9.81M | Buy |
413,538
+326,964
| +378% | +$7.38M | 0.02% | 644 |
|
|
2015
Q1 | $2.07M | Sell |
86,574
-225,828
| -72% | -$5.07M | ﹤0.01% | 856 |
|
|
2014
Q4 | $6.63M | Buy |
+312,402
| New | +$6.28M | 0.01% | 735 |
|
|
2014
Q3 | – | Sell |
-57,600
| Closed | -$824K | – | 1457 |
|
|
2014
Q2 | $824K | Sell |
57,600
-4,800
| -8% | -$65.1K | ﹤0.01% | 1005 |
|
|
2014
Q1 | $771K | Sell |
62,400
-488,400
| -89% | -$5.64M | ﹤0.01% | 1006 |
|
|
2013
Q4 | $6.04M | Buy |
+550,800
| New | +$6.21M | 0.01% | 761 |
|
Other funds holding EW
Schroder Investment Management Group's EW Position: Q2 2024 in Review
Schroder Investment Management Group sold out of Edwards Lifesciences (EW) in Q2 2024, closing a stake of 649,980 shares — an estimated $62.1M sold.
Schroder Investment Management Group first reported a position in EW in Q4 2013 and held it in 35 quarters. The position peaked at $374M in Q4 2021. 1,295 funds tracked by Wall St. Rank hold EW as of Q2 2024.
- Schroder Investment Management Group reported no remaining Edwards Lifesciences position as of Q2 2024 after selling out during the quarter.
- Schroder Investment Management Group sold 649,980 Edwards Lifesciences shares in Q2 2024, an estimated $62.1M.
- Schroder Investment Management Group first reported a position in Edwards Lifesciences in Q4 2013 and held it in 35 quarters.
- Schroder Investment Management Group's Edwards Lifesciences position peaked at $374M in Q4 2021.
- 1,295 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2024.
Based on Schroder Investment Management Group's 13F filing for Q2 2024, filed 12 Aug 2024.